Sign in:
Email
 Password  save:
  
 Company Reports 
 
   
My Recent Searches
  Help
 
   
 
 
Get Insiders for : 
Mirati Therapeutics, Inc. (MRTX)  
$58.70 0.00 (0.00%) as of 4:30 Mon 1/22


Download
   
Exchange: N/A
Security Type: N/A
Shares Out: 83,668,000
Market Cap: 4.91(B)
Last Volume: 0 Avg Vol: 0
52 Week Range: $27.8 - $62.38
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:

   

Rankings:

     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Mirati Therapeutics is a clinical-stage oncology company developing product candidates to address the genetic and immunological promoters of cancer. Co.'s KRAS inhibitor program is focused on developing inhibitors of KRAS mutations and includes one clinical candidate and a preclinical program. Co. also has additional preclinical programs which include product candidates designed to address mutations and tumors where few treatment options exist. Co.'s clinical and preclinical programs consist of two product candidates: sitravatinib, a multi-kinase inhibitor and MRTX849, a KRAS G12C inhibitor. Co. has several discovery programs, including a preclinical program for a KRAS G12D inhibitor.


 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 1,269,764 1,269,764
Total Buy Value $0 $0 $35,299,439 $35,299,439
Total People Bought 0 0 2 2
Total Buy Transactions 0 0 3 3
Total Shares Sold 0 11,422 19,076 136,645
Total Sell Value $0 $664,751 $950,088 $10,440,645
Total People Sold 0 2 3 7
Total Sell Transactions 0 6 9 23
End Date 2024-01-28 2023-10-27 2023-04-28 2022-04-28

   
Records found: 370
  Page 3 of 15  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

 
3m +/-  
Form
   Stelzer Laurie Chief Financial Officer   •       –      –    2023-06-02 4 S $37.06 $172,218 D/D (4,647) 80,015 -48%     
   Christensen Jamie EVP & Chief Scientific Officer   •       –      –    2023-05-24 4 S $45.29 $28,035 D/D (619) 124,123 0%     
   Carter Bruce L A   –       •      –    2023-01-20 4 A $0.00 $0 D/D 4,444 10,465     -
   Cherrington Julie M   –       •      –    2023-01-20 4 A $0.00 $0 D/D 4,444 4,444     -
   Sharp Shalini   –       •      –    2023-01-20 4 A $0.00 $0 D/D 4,444 9,414     -
   Davis Aaron I.   –       •       •   2023-01-20 4 A $0.00 $0 D/D 4,444 47,517     -
   Hasnain Faheem   –       •      –    2023-01-20 4 A $0.00 $0 D/D 6,333 15,050     -
   Martinez Maria E   –       •      –    2023-01-20 4 A $0.00 $0 D/D 4,444 10,465     -
   Meek David D. Chief Executive Officer   •       •      –    2023-01-20 4 A $0.00 $0 D/D 89,379 151,171     -
   Stelzer Laurie CFO   •       –      –    2023-01-20 4 A $0.00 $0 D/D 26,864 84,662     -
   Fuchs Henry J   –       •      –    2023-01-20 4 A $0.00 $0 D/D 4,444 10,465     -
   Hickey Benjamin EVP, Chief Commercial Officer   •       –      –    2023-01-20 4 A $0.00 $0 D/D 36,394 83,617     -
   Baum Charles M President,Founder,Head of R&D   •       •      –    2023-01-20 4 A $0.00 $0 D/D 4,444 173,221     -
   Johnson Craig A   –       •      –    2023-01-20 4 A $0.00 $0 D/D 4,444 10,465     -
   Christensen Jamie EVP, Chief Scientific Officer   •       –      –    2023-01-20 4 A $0.00 $0 D/D 26,864 124,742     -
   Cherrington Julie M   –       •      –    2023-01-18 4 AS $44.66 $113,704 D/D (2,546) 0 -14%     
   Meek David D. Chief Executive Officer   •       •      –    2023-01-17 4 S $42.38 $134,715 D/D (3,179) 61,792 13%     
   Hickey Benjamin EVP, Chief Commercial Officer   •       –      –    2023-01-17 4 S $42.38 $66,366 D/D (1,566) 47,223 13%     
   Christensen Jamie EVP, Chief Scientific Officer   •       –      –    2023-01-17 4 S $42.38 $95,142 D/D (2,245) 97,878 13%     
   Hickey Benjamin EVP, Chief Commercial Officer   •       –      –    2023-01-09 4 S $45.37 $94,733 D/D (2,088) 48,789 -13%     
   Baum Charles M President,Founder,Head of R&D   •       •      –    2023-01-04 4 S $46.60 $169,997 D/D (3,648) 168,777 -3%     
   Christensen Jamie EVP, Chief Scientific Officer   •       –      –    2023-01-04 4 S $46.60 $90,823 D/D (1,949) 100,123 -3%     
   Hickey Benjamin EVP, Chief Commercial Officer   •       –      –    2022-12-21 4 S $40.41 $131,266 D/D (3,248) 50,877 -10%     
   Baum Charles M President,Founder,Head of R&D   •       •      –    2022-12-21 4 S $40.42 $367,469 D/D (9,092) 172,425 -10%     
   Meek David D. Chief Executive Officer   •       •      –    2022-12-21 4 S $40.41 $186,552 D/D (4,616) 64,971 -10%     

  370 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 3 of 15
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed